Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10001736HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018435HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018666HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018683HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018721HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018731HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018795HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10018876HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10038171HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TVIS10038910HBVENSG00000171132.14protein_codingPRKCENoNo5581L7RTI5
Q02156
TCGA Plot Options
Drug Information
GenePRKCE
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0003431
UniProt IDQ02156
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830